Computable Genomix Secures Investment for Developing Genetic Biomarker Test Process

Memphis-based Computable Genomix today announced that it has secured an investment to pilot a novel process for developing genetic biomarker tests.

Biomarkers are used to predict how a person will respond to drug therapy or to determine their risk of contracting a disease.

Leveraging its next-generation computational discovery capability (patent-pending), Computable Genomix is developing highly targeted genetic biomarker tests for clinical researchers. These tests will help address pressing pharmacogenomic and other clinical questions and enhance the ability of physicians to bring personalized medicine to their patients.

“Current approaches to genetic biomarker development require clinical researchers to work with thousands of patient samples and sift through millions of possibilities to pinpoint a handful of potential biomarkers for further evaluation,” said Brad Silver, chief executive officer of Computable Genomix. “Using Computable’s very targeted tests, clinical researchers need fewer patient samples to assess a small number of high-value biomarkers. The end result is savings of time and money.”

Memphis-based venture capital firm Innova is funding Computable’s effort to stake a claim in the exploding, multi-billion dollar biomarker market “As an incubator company at the Memphis Bioworks Foundation, we have closely followed the evolution of Computable Genomix from a supplier of software to a developer of proprietary biomarker tests,” said Innova partner Jan Bouten. “We are very excited about Computable’s opportunity in the burgeoning biomarker market and its prospects for accelerating their use in clinical practice.”

Speaking to the company’s new business model, Silver said, “after supplying our software to several leading research institutions, we quickly recognized that development of biomarkers is the best way to extract maximum value from our very powerful discovery capability. Once we identified this opportunity, it came down to building and funding the biomarker development process.”

Source: http://www.computablegenomix.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.